Single User
£3750
PDF
38 pages

Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025


Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. The disease is idiopathic, although a number of possible causes have been identified, including exposure to various dusts and smoking. This report provides the current prevalent population for IPF across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a breakdown of the course of the disease, progressive vs. stable, with the definite diagnosed IPF patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of IPF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for IPF include:

  • GORD
  • Cardiovascular Disease
  • Presence of clubbing
  • Air ventilation assistance

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global IPF market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of IPF and identify patient segments with high potential. This would include patients diagnosed with definite or probable IPF.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on IPF’s prevalent population.
  • Identify sub-populations within IPF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of IPF patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors and Prevention
  • Diagnosis of the Disease
  • Variation by Geography/ Ethnicity
  • Disease Prognosis and Clinical Course
  • Key Co-Morbid Conditions / Features associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Idiopathic Pulmonary Fibrosis
    • Type of IPF
    • GAP Staging
    • Co-morbid Conditions in IPF
    • Air Ventilation Assistance in IPF Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables and Figures
  • GAP Index for IPF Staging
  • Gap Staging System
  • Prevalence of IPF, total (000s)
  • Prevalence of IPF, males (000s)
  • Prevalence of IPF, females (000s)
  • Type of IPF present in patients, total (000s)
  • Course of disease in definite IPF patients, total (000s)
  • GAP stages in patients with definite IPF, total (000s)
  • GORD in patients with IPF, total (000s)
  • Presence of clubbing in patients with IPF, total (000s)
  • Cardiovascular disease in patients with IPF, total (000s)
  • Supplemental oxygen use in patients with IPF, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of IPF by 5-yr age cohort, males (000s)
  • USA Prevalence of IPF by 5-yr age cohort, females (000s)
  • France Prevalence of IPF by 5-yr age cohort, males (000s)
  • France Prevalence of IPF by 5-yr age cohort, females (000s)
  • Germany Prevalence of IPF by 5-yr age cohort, males (000s)
  • Germany Prevalence of IPF by 5-yr age cohort, females (000s)
  • Italy Prevalence of IPF by 5-yr age cohort, males (000s)
  • Italy Prevalence of IPF by 5-yr age cohort, females (000s)
  • Spain Prevalence of IPF by 5-yr age cohort, males (000s)
  • Spain Prevalence of IPF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of IPF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of IPF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of IPF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of IPF by 5-yr age cohort, females (000s)
  • Japan Prevalence of IPF by 5-yr age cohort, males (000s)
  • Japan Prevalence of IPF by 5-yr age cohort, females (000s)
  • India Prevalence of IPF by 5-yr age cohort, males (000s)
  • India Prevalence of IPF by 5-yr age cohort, females (000s)
Brazil, France, Germany, India, Italy, Japan, Spain, United Kingdom, United States of America